Rockwell Medical, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; unaudited. Rockwell develops, manufactures and distributes hemodialysis products, with concentrates as its primary business. Unless otherwise noted, amounts below are in U.S. dollars.
Key financial results
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Net sales | $19.7 million | $16.1 million |
| Gross profit (loss) | $2.6 million; 13.2% margin | $(0.8) million; (4.9)% margin |
| Operating loss | $(1.4) million | $(6.6) million |
| Net loss | $(1.8) million | $(7.2) million |
| Net loss per share | $(0.10) | $(0.84) |
| Cash used in operating activities | $3.9 million | $9.8 million |
Financial position and material changes
- At March 31, 2023, cash and cash equivalents were $10.9 million and available-for-sale investments were $5.9 million, totaling approximately $16.8 million. Working capital was $14.6 million.
- Total assets were $40.5 million and total liabilities were $27.9 million. Term-loan principal was $10.0 million, with a reported net carrying value of $9.3 million. The loan matures March 2025; scheduled payments resume in September 2023. The company said it was in compliance with loan covenants.
- Sales rose 22% year over year, primarily due to the revised DaVita supply agreement, new customer onboarding and higher pricing for other customers. Gross profit improved by $3.4 million, also reflecting $1.5 million of remaining deferred revenue recognized after the Baxter distribution agreement ended.
- Research and product development expense declined to $0.3 million from $1.6 million, mainly due to cost management and putting the FPC home-infusion program on hold. General and administrative expense fell to $3.3 million from $3.8 million.
- Investing activities provided $5.3 million, mainly reflecting net sales of available-for-sale investments. Cash increased by $0.8 million during the quarter.
Outlook, risks and unusual items
- Management expects improved margins for the remainder of 2023 and states a goal of achieving profitability in 2024. These are targets, not assurances.
- Management believes available working capital will fund operations for at least 12 months from the filing date, but says additional capital may be needed. Financing availability and terms are uncertain; Form S-3 baby-shelf limits may constrain equity issuance.
- DaVita represented approximately 48% of sales and 34% of accounts receivable at quarter-end, creating customer concentration exposure.
- The company reacquired U.S. distribution rights from Baxter and transitioned sales to its own distribution. The $1.5 million of Baxter-related deferred revenue recognized in Q1 is a notable item and may not recur on the same basis.
- Rockwell discontinued U.S. commercialization and its U.S. NDAs for Triferic; international partner programs continue, while work in India, Peru and Chile is on hold. Home-infusion FPC development is also on hold. The company is evaluating FPC’s potential for other indications.
- Potential dilution is significant: at March 31, 2023, 5.911 million pre-funded warrants and 9.901 million other warrants were outstanding, in addition to preferred-stock conversion rights and equity awards. The company reported 12.553 million common shares outstanding at quarter-end; its basic and diluted weighted-average share count was 18.360 million, including pre-funded warrant shares treated as outstanding for EPS. A further 1.191 million pre-funded warrants were exercised after quarter-end for nominal proceeds.
- The filing cites macroeconomic and funding-market uncertainty, including inflation, interest rates, supply-chain conditions and geopolitical risks. Routine legal proceedings were not expected to have a material effect; no material changes to the prior annual report’s risk factors were reported.
Important facts for investors to verify
- Whether sales growth and improved concentrate margins persist after the transition from Baxter and the recognition of deferred revenue.
- Customer retention, new-customer contributions and continuing reliance on DaVita.
- Operating cash burn, available financing capacity and compliance with Innovatus loan covenants as scheduled principal payments resume.
- Potential share dilution from warrants, preferred stock and other equity awards.
- Progress and commercial prospects for international Triferic partnerships and any future FPC development.